About
Company Overview
Management Team
Board of Directors
Advisors
Partnering
Careers
CBD
Programs
Overview
Graft versus Host Disease (GVHD)
Acute and Chronic Pain
Additional Preclinical Programs
News
Investors
Investor Overview
Press Releases
Company Information
SEDAR Filings
SEC Filings
Stock Information
Corporate Governance
Contact
About
Company Overview
Management Team
Board of Directors
Advisors
Partnering
Careers
CBD
Programs
Overview
Graft versus Host Disease (GVHD)
Acute and Chronic Pain
Additional Preclinical Programs
News
Investors
Investor Overview
Press Releases
Company Information
SEDAR Filings
SEC Filings
Stock Information
Corporate Governance
Contact
Press Releases
Menu
Overview
Press Releases
Company Information
Stock Information
SEC Filings
Corporate Governance
Recent Press Releases
Kalytera Therapeutics Announces Filing of Short Form Prospectus
April 17, 2019
Kalytera Therapeutics Announces Short Form Prospectus Offering of Units
April 3, 2019
Kalytera Reports Data for First Cohort in Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD
March 22, 2019
Kalytera Announces Closing of Private Placement of Convertible Debenture Units
March 7, 2019
Kalytera Announces Initiation of Study KAL-07 – Food Effect Study
March 6, 2019
Kalytera Announces Private Placement of Convertible Debenture Units
March 5, 2019
Kalytera Announces Share Issuance for January Invoices under Payments Agreements with Salzman Group
February 26, 2019
View all News and Insights
Browse by Year
2019
2018
2017
2016
2015
